FSD Pharma Inc. Files 6-K Update
Ticker: QNTM · Form: 6-K · Filed: May 16, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | May 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: update, filing, press-release
TL;DR
FSD Pharma dropped a 6-K update on May 16th, check the press release for deets.
AI Summary
FSD Pharma Inc. filed a Form 6-K on May 16, 2024, to provide an update. The filing includes a press release (Exhibit 99.1) which details the company's progress. Nathan Coyle, Chief Financial Officer, signed the report.
Why It Matters
This filing indicates FSD Pharma Inc. is actively communicating updates to investors, which is crucial for transparency and market awareness.
Risk Assessment
Risk Level: low — This is a routine filing providing an update and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- Nathan Coyle (person) — Chief Financial Officer
- May 16, 2024 (date) — Filing Date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report an update from FSD Pharma Inc., including a press release as Exhibit 99.1.
Who signed the Form 6-K on behalf of FSD Pharma Inc.?
Nathan Coyle, Chief Financial Officer, signed the Form 6-K on behalf of FSD Pharma Inc.
What is the Commission File Number for FSD Pharma Inc.?
The Commission File Number for FSD Pharma Inc. is 001-39152.
What is the address of FSD Pharma Inc.'s principal executive office?
The address of FSD Pharma Inc.'s principal executive office is 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada.
Which exhibit is included with this Form 6-K filing?
Exhibit 99.1, a Press Release, is included with this Form 6-K filing.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-05-16 08:01:56
Filing Documents
- fsd_6k.htm (6-K) — 9KB
- fsd_ex991.htm (EX-99.1) — 20KB
- 0001654954-24-006456.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: May 16, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3